Sign In
Buy XTNT
Xtant Medical Holdings Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0200 |
| EPS Surprise | -33.33% |
| Revenue estimate | 20.164M |
| Revenue actual | 20.884M |
| Revenue Surprise | 3.57% |
| Release date | Mar 31, 2026 |
| EPS estimate | -$0.0049 |
| EPS actual | $0.0004 |
| EPS Surprise | 108.16% |
| Revenue estimate | 30.755M |
| Revenue actual | 32.357M |
| Revenue Surprise | 5.21% |
| Release date | Nov 10, 2025 |
| EPS estimate | -$0.0053 |
| EPS actual | $0.0100 |
| EPS Surprise | 290.48% |
| Revenue estimate | 30.75M |
| Revenue actual | 33.255M |
| Revenue Surprise | 8.15% |
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.0200 |
| EPS Surprise | 300.00% |
| Revenue estimate | 31.2M |
| Revenue actual | 35.411M |
| Revenue Surprise | 13.50% |
Last 4 Quarters for Xtant Medical Holdings
Below you can see how XTNT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 12, 2025 |
| Price on release | $0.670 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.0200 |
| EPS surprise | 300.00% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $0.570 |
| Aug 07, 2025 | $0.628 |
| Aug 08, 2025 | $0.620 |
| Aug 11, 2025 | $0.587 |
| Aug 12, 2025 | $0.670 |
| Aug 13, 2025 | $0.649 |
| Aug 14, 2025 | $0.650 |
| Aug 15, 2025 | $0.632 |
| Aug 18, 2025 | $0.650 |
| 4 days before | 17.54% |
| 4 days after | -3.01% |
| On release day | -3.07% |
| Change in period | 14.00% |
| Release date | Nov 10, 2025 |
| Price on release | $0.761 |
| EPS estimate | -$0.0053 |
| EPS actual | $0.0100 |
| EPS surprise | 290.48% |
| Date | Price |
|---|---|
| Nov 04, 2025 | $0.742 |
| Nov 05, 2025 | $0.798 |
| Nov 06, 2025 | $0.790 |
| Nov 07, 2025 | $0.753 |
| Nov 10, 2025 | $0.761 |
| Nov 11, 2025 | $0.756 |
| Nov 12, 2025 | $0.722 |
| Nov 13, 2025 | $0.660 |
| Nov 14, 2025 | $0.666 |
| 4 days before | 2.56% |
| 4 days after | -12.54% |
| On release day | -0.618% |
| Change in period | -10.30% |
| Release date | Mar 31, 2026 |
| Price on release | $0.558 |
| EPS estimate | -$0.0049 |
| EPS actual | $0.0004 |
| EPS surprise | 108.16% |
| Date | Price |
|---|---|
| Mar 25, 2026 | $0.563 |
| Mar 26, 2026 | $0.566 |
| Mar 27, 2026 | $0.553 |
| Mar 30, 2026 | $0.543 |
| Mar 31, 2026 | $0.558 |
| Apr 01, 2026 | $0.532 |
| Apr 02, 2026 | $0.492 |
| Apr 06, 2026 | $0.450 |
| Apr 07, 2026 | $0.456 |
| 4 days before | -0.91% |
| 4 days after | -18.28% |
| On release day | -4.64% |
| Change in period | -19.02% |
| Release date | May 13, 2026 |
| Price on release | $0.480 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0200 |
| EPS surprise | -33.33% |
| Date | Price |
|---|---|
| May 07, 2026 | $0.570 |
| May 08, 2026 | $0.520 |
| May 11, 2026 | $0.523 |
| May 12, 2026 | $0.504 |
| May 13, 2026 | $0.480 |
| May 14, 2026 | $0.470 |
| May 15, 2026 | $0.456 |
| May 18, 2026 | $0.456 |
| May 19, 2026 | $0.459 |
| 4 days before | -15.79% |
| 4 days after | -4.37% |
| On release day | -2.08% |
| Change in period | -19.47% |
Xtant Medical Holdings Earnings Call Transcript Summary of Q1 2026
Xtant Medical reported Q1 2026 revenue of $20.9M, and management raised full-year 2026 revenue guidance to $101M–$105M. The company closed a transformational distribution/license agreement with Dilon Technologies for exclusive U.S. rights to HEMOBLAST Bellows, entering an estimated $2B hemostatic market and adding 21 experienced sales reps to expand commercial reach. Xtant completed the Companion Spine divestiture and received the final $10.7M payment, using proceeds to reduce debt and strengthen liquidity; total indebtedness was materially reduced in Q1. The company launched Trivium Shaped (pre-shaped allograft forms) to extend its Trivium bone graft platform and emphasized its broad biologics portfolio across five orthopedic categories as a competitive differentiator. Gross margin in Q1 was 57.3% (down from 61.5% YoY) due mainly to lost amnio license Q-code revenue; operating expenses declined following the divestiture. Net loss was $3.1M ($0.02/share); adjusted EBITDA was a loss of $1.6M. Management expects gross margins to recover to the low-60s later in the year and forecasts accelerating biologics-driven growth as new products and the expanded sales force scale.
